NEW YORK (GenomeWeb News) – BioMérieux and Knome announced today that they will collaborate on developing next-generation sequencing-based molecular diagnostics.
The collaboration includes the French diagnostics firm taking a $5 million equity stake in Knome. Though the firms did not disclose the details of the investment or further financial terms, they said that BioMérieux has the right to designate one director for election to the board of directors of privately held Knome.
Under terms of the agreement, BioMérieux will have exclusive rights to license Knome's genome analysis platform for use in the in vitro diagnostics market. In return, Knome gains access to BioMérieux's intellectual property in DNA extraction and sample preparation.
BioMérieux said that developing multiplex, DNA sequencing-based diagnostics is part of its 2015 strategic roadmap. The firm said that it intends to develop next-generation cancer and infectious disease diagnostics using Knome's sequence analysis technology and bioinformatic tools.
Cambridge, Mass.-based Knome, which launched in late 2007 as a personal genomics firm, last year inked a deal with SeqWright, under which Knome's personal genome sequencing and analysis service is offered through SeqWright's CLIA-certified laboratory.